REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS Russian patent published in 2021 - IPC A61K31/4178 A61K31/4192 A61K39/395 A61P35/00 

FIELD: medicine; pharmacy.

SUBSTANCE: group of inventions relates to medicine and pharmacy. The first object is a method of treating a subject with triple negative breast cancer. According to the method, a therapeutically effective amount of a CCR1 chemokine receptor antagonist and a therapeutically effective amount of a PD-1 inhibitor or PD-L1 inhibitor are administered to an individual in need thereof. The CCR1 chemokine receptor antagonist is a compound of formula (IIIb1a):

(IIIb1a),

where each A is N or CH and at least one A is N; R¹ is a halogen; R³ is selected from the group consisting of C_1-8 alkyl, C_3-8 cycloalkyl, and C_2-8 alkenyl; and R⁸ is C_1-8 alkyl; or a pharmaceutically acceptable salt thereof. The second and third objects represent the respective composition and a kit.

EFFECT: synergistic effect of the combinations according to the invention in the treatment of triple negative breast cancer.

27 cl, 10 dwg, 1 tbl, 1 ex